UpdatesPress Release
Sai Life Sciences reported a strong Q1FY27: Revenue ₹554 Cr (+12% YoY), PAT ₹73 Cr (+22% YoY). CRO business grew 24%. A new 100,000 sq. ft.
Sai Life Sciences LimitedSAILIFE · Filed with the exchange
R&D facility operationalized.
Strategic pharma engagements and strong CMC pipeline drive multi-year growth outlook.
No comments yet. Be the first.